We are live on
!
Find out more
YIH
Y-Intercept (HK) Portfolio holdings
AUM
$5.05B
1-Year Est. Return
17.89%
This Fund
S&P 500
This Quarter
Est. Return
+8.56%
1 Year Est. Return
+17.89%
3 Year Est. Return
+34.37%
5 Year Est. Return
+20.59%
10 Year Est. Return
–
AUM
$678M
AUM Growth
-$321M
(-32%)
Cap. Flow
-$353M
Cap. Flow
% of AUM
-52.06%
Top 10 Holdings %
Top 10 Hldgs %
8.43%
Holding
1,464
New
537
Increased
157
Reduced
250
Closed
520
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$4.58M |
| 2 |
CrowdStrike
CRWD
|
+$3.75M |
| 3 |
L3Harris
LHX
|
+$3.23M |
| 4 |
Johnson & Johnson
JNJ
|
+$3.1M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$2.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chevron
CVX
|
+$12.7M |
| 2 |
Verizon
VZ
|
+$9.98M |
| 3 |
Comcast
CMCSA
|
+$7.56M |
| 4 |
Ford
F
|
+$6.17M |
| 5 |
American Electric Power
AEP
|
+$5.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.33% |
| 2 | Financials | 14.02% |
| 3 | Healthcare | 13.64% |
| 4 | Industrials | 11.99% |
| 5 | Consumer Discretionary | 11.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAFE
901
Safehold
SAFE
$1.19B
| $79.7K | 0.01% |
1,671
-2,561
| -61% | -$123K |
|
902
Coeur Mining
CDE
$15.4B
| $77.4K | 0.01% |
+23,049
| New | +$81.9K |
|
903
Sabre
SABR
$743M
| $77.4K | 0.01% |
+12,530
| New | +$69.9K |
|
|
FSP
904
Franklin Street Properties
FSP
$50.1M
| $77.2K | 0.01% |
28,289
+17,260
| +156% | +$47.8K |
|
905
Hudbay
HBM
$9.67B
| $75.6K | 0.01% |
+14,912
| New | +$71.8K |
|
906
Aurinia Pharmaceuticals
AUPH
$1.92B
| $72.6K | 0.01% |
+16,796
| New | +$97.5K |
|
907
8x8 Inc
EGHT
$271M
| $70.8K | 0.01% |
+16,389
| New | +$65.9K |
|
|
VBIV
908
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $65.5K | 0.01% |
+5,586
| New | +$98.5K |
|
|
NGM
909
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $62.6K | 0.01% |
+12,475
| New | +$78.2K |
|
910
Atara Biotherapeutics
ATRA
$70.4M
| $61.7K | 0.01% |
+753
| New | +$78.5K |
|
|
TGAN
911
DELISTED
Transphorm, Inc. Common Stock
TGAN
| $61.3K | 0.01% |
+11,272
| New | +$66.3K |
|
912
Gerdau
GGB
$9.72B
| $57.2K | 0.01% |
+13,008
| New | +$56K |
|
|
ADTH
913
DELISTED
AdTheorent Holding Co
ADTH
| $57K | 0.01% |
+34,343
| New | +$66.2K |
|
|
TTSH
914
DELISTED
Tile Shop Holdings
TTSH
| $55K | 0.01% |
+12,552
| New | +$51.6K |
|
|
LTCH
915
DELISTED
Latch, Inc. Common Stock
LTCH
| $54K | 0.01% |
+76,104
| New | +$69.7K |
|
|
ADAM
916
Adamas Trust
ADAM
$783M
| $51.7K | 0.01% |
5,053
+1,624
| +47% | +$17.3K |
|
917
Karyopharm Therapeutics
KPTI
$161M
| $51.3K | 0.01% |
1,006
+315
| +46% | +$21.8K |
|
|
QUOT
918
DELISTED
Quotient Technology Inc
QUOT
| $46.3K | 0.01% |
+13,499
| New | +$38.2K |
|
|
SRTA
919
Strata Critical Medical Inc
SRTA
$440M
| $45.4K | 0.01% |
+12,668
| New | +$54.1K |
|
920
Aveanna Healthcare
AVAH
$2.15B
| $41.9K | 0.01% |
+53,716
| New | +$56.2K |
|
|
KORE
921
DELISTED
KORE Group Holdings
KORE
| $41.4K | 0.01% |
+6,578
| New | +$75.7K |
|
|
AUD
922
DELISTED
Audacy, Inc.
AUD
| $40.2K | 0.01% |
+178,608
| New | +$56.2K |
|
923
Inseego
INSG
$111M
| $39.7K | 0.01% |
+4,716
| New | +$70.8K |
|
|
BNR
924
Burning Rock Biotech
BNR
$96.9M
| $39K | 0.01% |
1,732
+577
| +50% | +$13.2K |
|
|
TRUE
925
DELISTED
TrueCar
TRUE
| $38.6K | 0.01% |
+15,365
| New | +$32K |
|
Similar funds
HSA
O
LIM
LFG
JIM
CTC
NL
BPWM
Y-Intercept (HK)'s Q4 2022 Portfolio in Review
As of Q4 2022, Y-Intercept (HK) held 1,464 positions worth $678M, down 32% from $1,000M the previous quarter. Its ten largest holdings account for 8.4% of the portfolio.
Y-Intercept (HK) withdrew a net $353M in Q4 2022, closing 520 positions and reducing 250 holdings. Its most notable exit was Verizon, an estimated $9.98M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Y-Intercept (HK) opened a new position in Bristol-Myers Squibb worth $4.37M.
- Y-Intercept (HK)'s largest Q4 2022 buy was Bristol-Myers Squibb: 60,782 shares worth $4.37M.
- Y-Intercept (HK) added most to Walmart Inc in Q4 2022, an estimated $2.76M increase.
- Y-Intercept (HK)'s biggest Q4 2022 reduction was Chevron, cutting an estimated $12.7M.
- Y-Intercept (HK) fully exited Verizon in Q4 2022, selling an estimated $9.98M.
- Y-Intercept (HK)'s ten largest holdings make up 8.4% of its $678M portfolio in Q4 2022.
- Y-Intercept (HK) opened 537 new positions and closed 520 in Q4 2022.
- Y-Intercept (HK)'s portfolio value fell 32% quarter-over-quarter to $678M.
Based on Y-Intercept (HK)'s 13F filing for Q4 2022, filed 14 Feb 2023.